Skip to main content
. 2020 Jul 30;94(16):e00514-20. doi: 10.1128/JVI.00514-20

TABLE 2.

Response of acute Env clones to the inhibition by SERINC5 and IFITM3

Acute Enva Subtype Fold inhibition by SERINC5b Fold inhibition by IFITM3c
CRF02_AG clone 235 A/G 1.13 ± 0.55 1.57 ± 0.25
CRF02_AG clone 242 A/G 2.08 ± 0.64 6.83 ± 1.19
CRF02_AG clone 250 A/G 9.18 ± 0.32 4.75 ± 1.54
CRF02_AG clone 251 A/G 0.54 ± 0.11 2.28 ± 0.51
Subtype G clone 252 A/G 0.41 ± 0.09 5.8 ± 0.66
CRF02_AG clone 255 A/G 1.74 ± 0.56 3.41 ± 0.88
CRF13_cpx clone 258 A/G 0.77 ± 0.11 1.7 ± 0.46
CRF02_AG clone 263 A/G 2.24 ± 0.66 8.06 ± 2.49
CRF02_AG clone 266 A/G 1.43 ± 0.24 4.57 ± 0.06
CRF02_AG clone 269 A/G 2.06 ± 0.60 2.78 ± 0.19
CRF02_AG clone 271 A/G 1.11 ± 0.18 11.61 ± 0.75
CRF02_AG clone 278 A/G 1.37 ± 0.40 14.7 ± 1.84
CRF02_AG clone 928 A/G 1.91 ± 0.07 10.67 ± 0.002
6535, clone 3 (SVPB5) B 11.83 ± 1.98 4.69 ± 0.54
PVO, clone 4 (SVPB11) B 0.96 ± 0-0.04 1.98 ± 0.13
TRO, clone 11 (SVP. B12) B 0.37 ± 0.03 5.66 ± 0.63
AC10.0, clone 29 (SVPB13) B 0.60 ± 0.15 6.50 ± 1.51
pREJO4541 clone 67 (SVPB16) B 3.86 ± 0.56 4.82 ± 0.67
pRHPA4259 clone 7 (SVPB14) B 2.177 ± 0.49 15.56 ± 1.0
pCAAN5342 clone A2 (SVPB19) B 0.71 ± 0.018 3.98 ± 0.40
Du156.12 C 1.17 ± 0.33 1.26 ± 0.20
Du172.17 C 1.40 ± 0.55 1.05 ± 0.005
ZM197M.PB7 C 4.26 ± 2.33 0.98 ± 0.09
ZM214M.PL15 C 2.28 ± 0.50 2.97 ± 0.39
ZM249M.PL1 C 2.84 ± 1.30 1.21 ± 0.03
ZM53M.PB12 C 1.58 ± 0.54 1.22 ± 0.14
ZM109F.PB4 C 5.10 ± 1.71 12.30 ± 0.63
ZM135M.PL10a C 3.87 ± 1.40 4.53 ± 0.64
CAP45.2.00.G3 C 5.00 ± 1.92 1.55 ± 0.17
CAP210.2.00.E8 C 2.46 ± 0.10 5.85 ± 0.14
HIV-001428-2 clone 42 C 1.04 ± 0.06 8.19 ± 0.52
HIV-16845-2 clone 22 C 0.95 ± 0.08 9.13 ± 0.39
HIV-16936-2 clone 21 C 1.57 ± 0.15 10.96 ± 0.70
HIV-25711-2 clone 4 C 3.80 ± 0.27 7.81 ± 0.04
HIV-25925-2 clone 22 C 1.52 ± 0.03 15.64 ± 4.07
a

All the Env clones are R5 tropic.

b

Fold inhibition by SERINC5 was determined by calculating the ratio of infectivity of the SERINC5-free virus to that of the SERINC5-bearing virus.

c

Fold inhibition by IFITM3 was determined by calculating the ratio of infectivity of the IFITM3-free virus to that of the IFITM3-bearing virus.